Oramed Pharmaceuticals Inc.

Regulatory Filings • Apr 19, 2024

SEC Form 4
------------

Instruction 1(b).

Reznick Yehuda

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

1. Name and Address of Reporting Person*

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

ORMP ]

04/17/2024

OMB APPROVAL

Other (specify

X Director 10% Owner

X Form filed by One Reporting Person Form filed by More than One Reporting

Officer (give title below)

Person

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934		OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
or Section 30(h) of the Investment Company Act of 1940
2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [	(Check all applicable)	5. Relationship of Reporting Person(s) to Issuer

Line)

1. Date of Earliest Transaction (Month/Day/Year) below)

2. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable

(Last) FLOOR	(First) 1185 AVENUE OF THE AMERICAS, THIRD	(Middle)
(Street) NEW YORK	NY	10036
(City)	(State)	(Zip)

Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction 2A. Deemed Date Execution Date, (Month/Day/Year) if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	(A) or Amount Price (D)		Transaction(s) (Instr. 3 and 4)
Common Stock	04/17/2024		A		29,800	A	(1)	29,800	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code V		(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents (i) a grant of 22,500 Restricted Stock Units ("RSUs") that will vest in equal installments on January 1, 2025, January 1, 2026 and January 1, 2027 and (ii) grants of 5,070 and 2,230 RSUs that will each vest in nearly equal installments on July 1, 2024, October 1, 2024 and January 1, 2025. In each case, the RSUs convert into the Issuer's Common Stock on a one-for-one basis.

/s/ Yehuda Reznick						04/18/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.